LEXINGTON, Mass.--(BUSINESS WIRE)-- Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that it has received a Paragraph IV Notice Letter from Hospira, Inc. advising of the filing of an ...
Accord Healthcare is voluntarily recalling 1 lot of Daptomycin for Injection 500mg/vial, and Daptomycin for Injection 350mg/vial to the consumer level due to a product mix-up. According to a product ...
Cubist Pharmaceuticals Issues Voluntary U.S. Recall of Certain Lots of CUBICIN (daptomycin for injection) 500 mg in 10 mL single use vials Due to Presence of Particulate Matter LEXINGTON, ...
December 13, 2010 — The US Food and Drug Administration (FDA) has approved a new delivery method for once-daily daptomycin injection (Cubicin; Cubist Pharmaceuticals, Inc), allowing its administration ...
In a 25-minute company presentation, Cubist's President & CEO, Michael W. Bonney, provided an update on the launch of the company's flagship product, Cubicin (TM) (daptomycin for injection), a ...
Accord Healthcare, Inc. is voluntarily recalling a single lot of Daptomycin for Injection 500 mg/vial, and Daptomycin for Injection 350 mg/vial product contained in cartons imprinted with lot # ...
LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi announced today it has introduced Daptomycin for Injection in the United States. Daptomycin for Injection, an antibiotic, is a generic alternative to ...
cubicin packaging Merck announced the launch of Cubicin RF (daptomycin for injection), a new formulation of Cubicin. Merck announced the launch of Cubicin RF (daptomycin for injection), a new ...
LEIPZIG, Germany ― Daptomycin (Cubicin, Cubist Pharmaceuticals) is safe and effective for the treatment of complicated skin infections in children, according to the results of a trial presented here ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results